Centro de Investigaciones Metabólicas (CINME) S.A. - CABA, Buenos Aires
CINME abre sus puertas en el 2007. Su misión es mejorar la calidad de vida de sus pacientes, a través de la atención médica asistencial humana e integral, siendo un centro educador para la comunidad y aportando datos cualitativos al avance científico en el marco de la investigación clínica. Hemos incorporado nuevas áreas terapéuticas en el campo de la salud, buscando ser en cada una un centro modelo para el diagnóstico y tratamiento de enfermedades, y al mismo tiempo de referencia en el campo de la investigación clínica. Teniendo como ideal la excelencia, hemos hecho especial énfasis en los procesos que nos aportan altos estándares de calidad en nuestro trabajo. Por ello, en el 2019 certificamos en calidad en los procesos de investigación clínica a través de IRAM-ISO 9001-2015.Viamonte, Cdad. Autónoma de Buenos Aires, Argentina
Websitehttp://www.cinme.com.ar
Select an option
I am a doctor
I am a sponsor
Specializations
Dermatitis atópica
Diabetes
Hepatitis autoinmune
Colitis ulcerosa
Enfermedad de Crohn
Fibrosis pulmonar
Fibrosis pulmonar idiopática
Cardiovascular
Nefropatía
Our team
Medical staff
Catalina Hermida
Regina Brandi
Gonzalo Saenz
Alejandra Romeo
Angela Romero Zarante
Mónica Rondinón
Liliana González
Mariana Abal
Ricardo Galimberti
Maria Laura Galimberti
Griselda Russo
María Otaola
Maria Otaola
Fernando Halac
Raquel Analia González
Estanislao Jesus Gomez
Maria Julia Garay
Gonzalo Saenz
Alberto Casey
Alberto Lorenzo Casey
Daniel Seinhart
Yésica Castillo
Yessica Castillo
Federico Carlos Perez Manghi
Maria de Lourdes Figuerola
María Margarita Anders
Estanislao Gómez
Adriana Ellenberg
Mariana Paula Blas
Maria Otaola
Lucas Manghi
Open studies
Diabetes
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity - Eli Lilly and CompanySee more
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) - Eli Lilly and CompanySee more
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) - TRANSCEND-T2D-3 - Eli Lilly and CompanySee more
A Research Study to See How Much CagriSema (1.0 mg Once Weekly) Lowers Blood Sugar and Body Weight Compared to Tirzepatide (5 mg Once Weekly) in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both - REIMAGINE 5 - Novo Nordisk A/SSee more
Obesity
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels - REDEFINE 3 - Novo Nordisk A/SSee more
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity - Eli Lilly and CompanySee more
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) - TRIUMPH-OUTCOMES - Eli Lilly and CompanySee more
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity - TRIUMPH-5 - Eli Lilly and CompanySee more
Cardiovascular disease
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels - REDEFINE 3 - Novo Nordisk A/SSee more
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes - CORALreef Outcomes - MK-0616-015 - Merck Sharp & Dohme LLCSee more
Alopecia
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata - BRAVE-AA-PEDS - Eli Lilly and CompanySee more
Alzheimer disease
Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease - PROGRESS-AD - GlaxoSmithKlineSee more
Breast Cancer
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment - PfizerSee more
Cardiac arrhythmia
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation - LIBREXIA-AF - Janssen Research & Development, LLCSee more
Chronic bronchitis
A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER) - PILASTER - Chiesi Farmaceutici S.p.A.See more
Chronic obstructive pulmonary disease
A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER) - PILASTER - Chiesi Farmaceutici S.p.A.See more
Hypercholesterolemia
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes - CORALreef Outcomes - MK-0616-015 - Merck Sharp & Dohme LLCSee more
Lung cancer
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) - GlaxoSmithKlineSee more
Lupus
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus - TOPAZ-2 - BiogenSee more
Rare diseases
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease. - Hoffmann-La RocheSee more
